Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

  • Mateo, F.
  • Arenas, E. J.
  • Aguilar, H.
  • Serra-Musach, J.
  • Ruiz de Garibay, G.
  • Boni, J.
  • Maicas, M.
  • Du, S.
  • Lorio, F.
  • Herranz-Ors, C.
  • Islam, A.
  • Prado, X.
  • Llorente, A.
  • Petit, A.
  • Vidal, A.
  • Catalá, I.
  • Soler, T.
  • Venturas, G.
  • Rojo-Sebastian, A.
  • Serra, H.
  • Cuadras, D.
  • Blanco, I.
  • Lozano, J.
  • Canals, F.
  • Sieuwerts, A. M.
  • Weerd, V. de
  • Look, M. P.
  • Puertas, S.
  • García, N.
  • Perkins, A. S.
  • Bonifaci, N.
  • Skowron, M.
  • Gómez-Baldó, L.
  • Hernández, V.
  • Martínez-Aranda, A.
  • Martínez-Iniesta, M.
  • Serrat, X.
  • Cerón, Julián
  • Brunet, J.
  • Barretina, M. P.
  • Gil, M.
  • Falo, C.
  • Fernández, A.
  • Morilla, I.
  • Pernas, S.
  • Plà, M. J.
  • Andreu, X.
  • Seguí, M. A.
  • Ballester, R.
  • Castellà, E.
  • Nellist. M.
  • Morales, S.
  • Valls, J.
  • Velasco, A.
  • Matias-Guiu, X.
  • Figueras, A.
  • Sánchez-Mut, José Vicente
  • Sánchez-Céspedes, M.
  • Cordero, A.
  • Gómez-Miragaya, J.
  • Palomero, L.
  • Gómez, A.
  • Gajewski, T. F.
  • Cohen, E. E. W.
  • Jesiotr, M.
  • Bodnar, L.
  • Quintela-Fandino, M.
  • López-Bigas, N.
  • Valdés-Mas, R.
  • Puente, X. S.
  • Viñals, F.
  • Casanovas, O.
  • Graupera, M.
  • Hernández-Losa, L.
  • Ramón y Cajal, S.
  • García-Alonso, L.
  • Sáez-Rodríguez, J.
  • Esteller, M.
  • Sierra, A.
  • Martín-Martín, N.
  • Matheu, A.
  • Carracedo, A.
  • González-Suárez, E.
  • Nanjundan, M.
  • Cortés, J.
  • Lázaro, C.
  • Odero, M. D.
  • Martens, J. W. M.
  • Moreno-Bueno, Gema
  • Barcellos-Hoff, M. H.
  • Villanueva, A.
  • Gomis, R. R.
  • Pujana, M. A.
13 páginas, 7 figuras, Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure., This study was supported by the following bodies and grants: the Scientific Foundation ‘Asociación Española Contra el Cáncer’ (AECC, Stable Coordinated Group, Hereditary Cancer); the BBVA Foundation; the Eugenio Rodríguez Pascual Foundation grant 2012; Generalitat de Catalunya AGAUR SGR 2012 grants 283, 290 and 312, and SGR 2014 grants 364, 530, and 535; Spanish Ministry of Health ISCIII FIS grants PI10/00057, PI10/00222, PI10/01422, PI12/01528, PI13/00132, and PI14/00336. ISCIII RTICC grants RD06/0020/1051, RD12/0036/0007, RD12/0036/0008 and RD12/0036/0063; Spanish Ministry of Science and Innovation, ‘Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa’, MINECO grants SAF2010- 20203 and SAF2013-46196; and the Telemaraton 2014 ‘Todos Somos Raros, Todos Somos Únicos’ grant P35. EJA was supported by ‘la Caixa’ PhD fellowship program, F Iorio was supported by a fellowship from the EMBL-EBI and the Wellcome Trust Sanger Institute Postdoctoral (ESPOD) program, and NL-B, ME and RRG were supported by ICREA., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies

  • Martínez Aranda, Antonio
  • Hernández, Vanessa
  • Guney, Emre|||0000-0002-3466-6535
  • Muixí, Laia
  • Foj Ibars, Rubén
  • Baixeras, Núria
  • Cuadras, Daniel|||0000-0001-8780-1764
  • Morros, Rosa|||0000-0001-6752-8748
  • Urruticoechea, Ander|||0000-0003-0359-3641
  • Gil, Miguel
  • Oliva Miguel, Baldomero|||0000-0003-0702-0250
  • Moreno, Ferran
  • González Suarez, Eva
  • Vidal, Noemí|||0000-0002-2852-6667
  • Andreu, Xavier
  • Seguí Palmer, Miguel Ángel|||0000-0002-5103-6746
  • Ballester Alabau, Rosa María
  • Castellà Fernández, Eva
  • Sierra-Jimenez, Angels|||0000-0003-1023-3492
Brain metastasis is a devastating problem in patients with breast, lung and melanoma tumors. GRP94 and FN14 are predictive biomarkers over-expressed in primary breast carcinomas that metastasized in brain. To further validate these brain metastasis biomarkers, we performed a multicenter study including 318 patients with breast carcinomas. Among these patients, there were 138 patients with metastasis, of whom 84 had brain metastasis. The likelihood of developing brain metastasis increased by 5.24-fold (95%CI 2.83-9.71) and 2.55- (95%CI 1.52-4.3) in the presence of FN14 and GRP94, respectively. Moreover, FN14 was more sensitive than ErbB2 (38.27 vs. 24.68) with similar specificity (89.43 vs. 89.55) to predict brain metastasis and had identical prognostic value than triple negative patients (p 0.0001). Furthermore, we used GRP94 and FN14 pathways and GUILD, a network-based disease-gene prioritization program, to pinpoint the genes likely to be therapeutic targets, which resulted in FN14 as the main modulator and thalidomide as the best scored drug. The treatment of mice with brain metastasis improves survival decreasing reactive astrocytes and angiogenesis, and down-regulate FN14 and its ligand TWEAK. In conclusion our results indicate that FN14 and GRP94 are prediction/prognosis markers which open up new possibilities for preventing/treating brain metastasis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease

  • Jiménez Pineda, Amanda|||0000-0003-4967-1174
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Montal, Victor|||0000-0002-5714-9282
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Pané, Adriana|||0000-0002-7810-1827
  • Casajoana, Anna
  • Belbin, Olivia|||0000-0002-6109-6371
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Moizé, Violeta
  • Vidal, Josep|||0000-0002-4564-4518
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Blesa, Rafael|||0000-0003-4026-2884
Weight loss has been proposed as a sign of pre-clinical Alzheimer Disease (AD). To test this hypothesis, we have evaluated the association between longitudinal changes in weight trajectories, cognitive performance, AD biomarker profiles and brain structure in 363 healthy controls from the Alzheimer's Disease Neuroimaging Initiative (mean follow-up 50.5±30.5 months). Subjects were classified according to body weight trajectory into a weight loss group (WLG; relative weight loss ≥ 5%) and a non-weight loss group (non-WLG; relative weight loss < 5%). Linear mixed effects models were used to estimate the effect of body weight changes on ADAS-Cognitive score across time. Baseline CSF tau/AΔ ratio and AV45 PET uptake were compared between WLG and non-WLG by analysis of covariance. Atrophy maps were compared between groups at baseline and longitudinally at a 2-year follow-up using Freesurfer. WLG showed increased baseline levels of cerebrospinal fluid tau/AΔ ratio, increased PET amyloid uptake and diminished cortical thickness at baseline. WLG also showed faster cognitive decline and faster longitudinal atrophy. Our data support weight loss as a non-cognitive manifestation of pre-clinical AD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

  • Mateo, Francesca|||0000-0002-2342-7010
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Aguilar, Helena
  • Serra-Musach, Jordi
  • Ruiz de Garibay, Gorka|||0000-0001-9936-8419
  • Boni, Jacopo|||0000-0003-2626-9393
  • Maicas, Miren|||0000-0003-1404-5552
  • Du, Shisuo
  • Iorio, Francesco|||0000-0001-7063-8913
  • Herranz-Ors, Carmen|||0000-0002-2866-0321
  • Islam, Abul
  • Prado, X.
  • Llorente, Alicia
  • Petit Montserrat, Anna|||0000-0002-9284-095X
  • Vidal, August|||0000-0001-5727-2099
  • Català, Isabel
  • Soler, Teresa
  • Venturas, G.
  • Rojo-Sebastian, Alejandro|||0000-0001-6439-3518
  • Serra, Helena
  • Cuadras, Daniel|||0000-0001-8780-1764
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Lozano, José
  • Canals, Francesc|||0000-0002-0650-1135
  • Sieuwerts, Anieta M.
  • De Weerd, Vanja
  • Look, Maxime P.
  • Puertas, Sara
  • García, Nadia
  • Perkins, Archibald S.
  • Bonifaci, Núria|||0000-0002-8193-6825
  • Skowron, Margaretha A.
  • Gómez-Baldó, Laia
  • Hernández, Vanessa
  • Martínez-Aranda, Antonio
  • Martínez-Iniesta, Maria|||0000-0001-6252-6671
  • Serrat Farran, Xènia|||0000-0001-7611-5400
  • Cerón, Julián|||0000-0003-4739-2243
  • Brunet, Joan|||0000-0003-1945-3512
  • Barretina-Ginesta, Maria-Pilar|||0000-0003-0074-6614
  • Gil, Mercedes|||0000-0002-7387-2139
  • Falo, Catalina|||0000-0002-5714-6823
  • Fernández, Adela
  • Morilla, Idoia
  • Pernas, Sonia|||0000-0002-1485-5080
  • Plà, Maria Jesus
  • Andreu, Xavier
  • Seguí Palmer, Miguel Ángel|||0000-0002-5103-6746
  • Ballester, Rosa|||0000-0002-7870-4185
  • Castellà Fernández, Eva
  • Nellist, Mark D.
  • Morales, Saleta
  • Valls, Joan|||0000-0002-4806-7568
  • Velasco Sánchez, Ana
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Figueras, Agnes
  • Sánchez-Mut, José Vicente|||0000-0002-9292-8521
  • Sánchez Céspedes, Montse|||0000-0002-6045-5627
  • Cordero Casanovas, Alex|||0000-0002-2224-7122
  • Gómez-Miragaya, Jorge|||0000-0003-1801-4681
  • Palomero, Luis|||0000-0002-9144-1017
  • Gomez-Caamaño, Antonio|||0000-0002-9773-4590
  • Gajewski, Thomas F.
  • Cohen, Ezra E. W.
  • Jesiotr, Marzena
  • Bodnar, Lubomir
  • Quintela-Fandino, Miguel|||0000-0003-1648-1964
  • Lopez-Bigas, Nuria|||0000-0003-4925-8988
  • Valdés-Mas, Rafael
  • Puente, Xose S.|||0000-0001-9525-1483
  • Viñals, Francesc|||0000-0002-9918-6751
  • Casanovas, Oriol|||0000-0002-4298-3995
  • Graupera, Mariona|||0000-0003-4608-4185
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • Garcia-Alonso, Luz|||0000-0002-7863-9619
  • Saez-Rodriguez, J.
  • Esteller, M.|||0000-0003-4490-6093
  • Sierra-Jimenez, Angels|||0000-0003-1023-3492
  • Martín-Martín, Natalia|||0000-0002-2527-429X
  • Matheu Fernandez, Ander
  • Carracedo, Arkaitz|||0000-0001-5957-1260
  • González-Suárez, Eva|||0000-0003-0858-8171
  • Nanjundan, Meera
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Odero, Maria D.|||0000-0002-8858-2054
  • Martens, John W. M.
  • Moreno-Bueno, Gema
  • Barcellos-Hoff, Mary Helen
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Gomis, Roger R.|||0000-0001-6473-2858
  • Pujana, Miguel Angel|||0000-0003-3222-4044
Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure.